Immunotherapy for Pediatric Cancer

Stephan A. Grupp, Michael Verneris, Paul M. Sondel, Laurence J.N. Cooper

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Improvements in adult cancer survivorship can be achieved from behavioral changes and adopting screening programs. Yet, these approaches cannot be readily applied to lower the morbidity and mortality from childhood cancers. Rather, pediatric oncologists must rely on procedures and therapies to treat, rather than prevent malignancies. The systematic application of chemotherapy, radiation therapy, and surgery has led to remarkable advances in survival but these improvements have come at a cost. Children routinely receive chemotherapy agents that were designed decades ago, and these drugs have predictable side effects that result in the loss of potential for long-term survivors. The advent of targeted applications of immune-based therapies offers children with cancer a new class of oncolytic therapies that may be used to treat disease refractory to conventional approaches and lessen the toxicity of current treatment regimens without compromising remission. This review explores how 3 components of the immune system-T cells, natural killer (NK) cells, and antibodies-can be used for therapy of pediatric malignancies.

Original languageEnglish (US)
Pages (from-to)33-43
Number of pages11
JournalBiology of Blood and Marrow Transplantation
Volume14
Issue number1 SUPPL.
DOIs
StatePublished - Jan 2008
Externally publishedYes

Fingerprint

Dive into the research topics of 'Immunotherapy for Pediatric Cancer'. Together they form a unique fingerprint.

Cite this